Jay T. Flatley Sells 15,000 Shares of Illumina, Inc. (ILMN) Stock

Illumina, Inc. (NASDAQ:ILMN) Director Jay T. Flatley sold 15,000 shares of the business’s stock in a transaction dated Tuesday, January 16th. The stock was sold at an average price of $243.72, for a total transaction of $3,655,800.00. Following the completion of the sale, the director now owns 449,201 shares in the company, valued at $109,479,267.72. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.

Illumina, Inc. (NASDAQ:ILMN) opened at $243.55 on Friday. Illumina, Inc. has a 52 week low of $156.50 and a 52 week high of $248.97. The company has a current ratio of 4.22, a quick ratio of 3.73 and a debt-to-equity ratio of 0.41. The company has a market cap of $35,560.00, a PE ratio of 45.95, a P/E/G ratio of 3.25 and a beta of 0.79.

Illumina (NASDAQ:ILMN) last released its quarterly earnings results on Tuesday, October 24th. The life sciences company reported $1.11 EPS for the quarter, topping analysts’ consensus estimates of $0.99 by $0.12. Illumina had a net margin of 30.34% and a return on equity of 19.42%. The firm had revenue of $714.00 million during the quarter, compared to analysts’ expectations of $692.77 million. During the same period in the previous year, the company earned $0.97 EPS. The firm’s revenue for the quarter was up 17.6% compared to the same quarter last year. analysts predict that Illumina, Inc. will post 3.76 earnings per share for the current year.

A number of analysts have recently weighed in on the stock. BTIG Research restated a “hold” rating on shares of Illumina in a report on Tuesday. Zacks Investment Research downgraded shares of Illumina from a “buy” rating to a “hold” rating in a report on Tuesday, October 31st. Canaccord Genuity restated a “buy” rating and issued a $230.00 target price (up from $215.00) on shares of Illumina in a report on Thursday, October 12th. Goldman Sachs Group restated a “neutral” rating and issued a $200.00 target price on shares of Illumina in a report on Tuesday, September 26th. Finally, Wells Fargo & Co upgraded shares of Illumina from a “market perform” rating to an “outperform” rating and set a $205.00 target price on the stock in a report on Tuesday, January 2nd. One investment analyst has rated the stock with a sell rating, nine have issued a hold rating and fourteen have issued a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $220.13.

Hedge funds have recently added to or reduced their stakes in the stock. Winslow Capital Management LLC purchased a new stake in Illumina in the 2nd quarter valued at about $211,584,000. Fred Alger Management Inc. boosted its position in Illumina by 611.9% in the 2nd quarter. Fred Alger Management Inc. now owns 637,597 shares of the life sciences company’s stock valued at $110,636,000 after buying an additional 548,030 shares during the period. Capital World Investors boosted its position in Illumina by 23.8% in the 2nd quarter. Capital World Investors now owns 2,135,000 shares of the life sciences company’s stock valued at $370,465,000 after buying an additional 410,000 shares during the period. Janus Henderson Group PLC boosted its position in Illumina by 1,556.2% in the 2nd quarter. Janus Henderson Group PLC now owns 330,010 shares of the life sciences company’s stock valued at $57,263,000 after buying an additional 310,084 shares during the period. Finally, Renaissance Technologies LLC purchased a new stake in Illumina in the 2nd quarter valued at about $47,010,000. 91.60% of the stock is owned by hedge funds and other institutional investors.

ILLEGAL ACTIVITY WARNING: This report was published by StockNewsTimes and is the sole property of of StockNewsTimes. If you are viewing this report on another publication, it was copied illegally and reposted in violation of international copyright & trademark legislation. The original version of this report can be read at https://stocknewstimes.com/2018/01/20/jay-t-flatley-sells-15000-shares-of-illumina-inc-ilmn-stock.html.

Illumina Company Profile

Illumina, Inc (Illumina) is a provider of sequencing- and array-based solutions for genetic analysis. The Company operates through two segments: Core Illumina and the consolidated variable interest entities (VIEs), which include the activities of GRAIL, Inc (GRAIL) and Helix Holdings I, LLC (Helix). Core Illumina consists of its core operations.

Insider Buying and Selling by Quarter for Illumina (NASDAQ:ILMN)

Receive News & Ratings for Illumina Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Illumina and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply